title: [A case of psoriasis induced by infliximab treatment for Crohn's disease].
abstract: Infliximab, the monoclonal antibody to tumor necrosis factor, is indicated for refractory luminal and fistulizing Crohn's disease and rheumatoid arthritis. Infliximab treatment has adverse events including infusion reactions, opportunistic infections, and the potential for the event such as reactivation of latent tuberculosis. Cutaneous adverse reactions of TNF-α agents include skin rash, urticaria, pruritus, lupus-like eruption, and injection site reactions. Most of all, psoriasis or psoriasiform dermatitis induced by infliximab treatment for Crohn's disease is rarely reported in Korea. We report a case of psoriasis induced by infliximab treatment for Crohn's disease with a review of world literature.
authors.affiliation: Department of Internal Medicine, lsan Paik Hospital, Inje University College of Medicine, Goyang, Korea.
authors.forename: Yoon Jung
authors.initials: YJ
authors.lastname: Jwa
authors.forename: Nam Hoon
authors.initials: NH
authors.lastname: Kim
authors.forename: Hai Jin
authors.initials: HJ
authors.lastname: Park
authors.forename: Jun Sup
authors.initials: JS
authors.lastname: Park
authors.forename: Won Ki
authors.initials: WK
authors.lastname: Bae
authors.forename: Kyung Ah
authors.initials: KA
authors.lastname: Kim
authors.forename: June Sung
authors.initials: JS
authors.lastname: Lee
authors.forename: Young Soo
authors.initials: YS
authors.lastname: Moon
mesh_terms: D000893:Anti-Inflammatory Agents / Q000009:adverse effects* / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D003113:Colonoscopy; D003424:Crohn Disease / Q000175:diagnosis / Q000188:drug therapy*; D005260:Female; D006801:Humans; D000069285:Infliximab; D011565:Psoriasis / Q000139:chemically induced* / Q000473:pathology / Q000628:therapy; D014466:Ultraviolet Rays; D055815:Young Adult
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D000069285:Infliximab